Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.50 |
| ▸ | STAMBP | O95630 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066741 | 0.86 | EGLN1 (0.69) | EGLN1FEN1KMT2A | |
| SCHEMBL4057517 | 0.83 | ADORA2A (0.53) | SMN1; SMN2EGLN1HPGDKDM4EHSD17B10 | |
| SCHEMBL5224738 | 0.82 | EGLN1 (0.57) | SMN1; SMN2EGLN1PSMD14STAMBPMAPK1 | |
| SCHEMBL2203862 | 0.82 | EGLN1 (0.74) | EGLN1HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL4067733 | 0.82 | ADORA2A (0.54) | EGLN1ADORA2AADORA2BFEN1 | |
| SCHEMBL4068615 | 0.81 | EGLN1 (0.55) | EGLN1KDM4ESTAMBPKMT2A | |
| SCHEMBL4068327 | 0.81 | EGLN1 (0.71) | EGLN1HPGDKDM4EPOLBLMNA | |
| SCHEMBL4062004 | 0.80 | EGLN1 (0.49) | EGLN1LMNAADORA2AADORA2BFEN1 | |
| SCHEMBL966559 | 0.80 | FEN1 (0.52) | EGLN1HPGDKDM4EALDH1A1FEN1 | |
| SCHEMBL4060463 | 0.80 | EGLN1 (0.57) | EGLN1POLBNPC1LMNAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | claimed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | claimed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | disclosed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | SMN1; SMN2 4869/4885EGLN1 1188/4885HPGD 2236/4885 |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | POLI, DUT, NAAA | SMN1; SMN2 3175/4885EGLN1 1994/4885HPGD 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.